{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:00:16Z","timestamp":1788454816225,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["ASPR-20-01495"],"award-info":[{"award-number":["ASPR-20-01495"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI146529"],"award-info":[{"award-number":["R21AI146529"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Army\u2019s Long Term Health and Education Training Program"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Influenza A virus (IAV) is a leading cause of respiratory disease worldwide often resulting in severe morbidity and mortality. We have previously shown that the Bacterial Enzymatic Combinatorial Chemistry (BECC) adjuvants, BECC438 and BECC470, formulated with an influenza virus hemagglutinin (HA) protein vaccine, offer greater protection from influenza virus challenge in mouse respiratory models using adult mice than standard HA:adjuvant combinations. In this study, we determined that immunization with HA\u2009+\u2009BECC adjuvants also significantly broadened the epitopes targeted on HA as compared with other adjuvants, resulting in increased titers of antibodies directed against the highly conserved HA stalk domain. Importantly, we demonstrate that BECC470 combined with an influenza virus HA protein antigen in a prime-only immunization regimen was able to achieve complete protection from challenge in a ~\u200912-month-old mouse aged model. Together, this demonstrates the heightened protection provided by the BECC470 adjuvant in an influenza virus vaccine model and shows the enhanced immune response, as compared to other adjuvants elicited by the formulation of HA with BECC470.<\/jats:p>","DOI":"10.1038\/s41598-023-27965-x","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T06:10:38Z","timestamp":1673590238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice"],"prefix":"10.1038","volume":"13","author":[{"given":"Robert","family":"Haupt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Baracco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Harberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumathi","family":"Loganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas J.","family":"Kerstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Frieman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"issue":"6","key":"27965_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19(6), 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"issue":"29","key":"27965_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.15585\/mmwr.mm7129a1","volume":"71","author":"A Merced-Morales","year":"2022","unstructured":"Merced-Morales, A. et al. Influenza activity and composition of the 2022\u201323 influenza vaccine\u2014United States, 2021\u201322 season. MMWR Morb. Mortal. Wkly. Rep. 71(29), 913\u2013919 (2022).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"10","key":"27965_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.15585\/mmwr.mm7110a1","volume":"71","author":"JR Chung","year":"2022","unstructured":"Chung, J. R. et al. Interim estimates of 2021\u201322 seasonal influenza vaccine effectiveness\u2014United States, February 2022. MMWR Morb. Mortal. Wkly. Rep. 71(10), 365\u2013370 (2022).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"1","key":"27965_CR4","doi-asserted-by":"publisher","first-page":"10432","DOI":"10.1038\/s41598-018-28706-1","volume":"8","author":"E Kirkpatrick","year":"2018","unstructured":"Kirkpatrick, E. et al. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci. Rep. 8(1), 10432 (2018).","journal-title":"Sci. Rep."},{"issue":"18","key":"27965_CR5","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1016\/j.vaccine.2022.02.088","volume":"40","author":"S Esposito","year":"2022","unstructured":"Esposito, S. et al. Efficacy and safety of a quadrivalent influenza vaccine in children aged 6\u201335 months: A global, multiseasonal, controlled, randomized Phase III study. Vaccine 40(18), 2626\u20132634 (2022).","journal-title":"Vaccine"},{"issue":"5","key":"27965_CR6","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2020.03.017","volume":"145","author":"CE Gustafson","year":"2020","unstructured":"Gustafson, C. E. et al. Influence of immune aging on vaccine responses. J. Allergy Clin. Immunol. 145(5), 1309\u20131321 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"issue":"37","key":"27965_CR7","doi-asserted-by":"publisher","DOI":"10.2807\/ese.15.37.19661-en","volume":"15","author":"H Kelly","year":"2010","unstructured":"Kelly, H. et al. Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010. Euro Surveill. 15(37), 19661 (2010).","journal-title":"Euro Surveill."},{"issue":"34","key":"27965_CR8","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1016\/j.vaccine.2022.07.002","volume":"40","author":"W Mimura","year":"2022","unstructured":"Mimura, W., Ishiguro, C. & Fukuda, H. Influenza vaccine effectiveness against hospitalization during the 2018\/2019 season among older persons aged >\/=75\u00a0years in Japan: The LIFE-VENUS Study. Vaccine 40(34), 5023\u20135029 (2022).","journal-title":"Vaccine"},{"issue":"31","key":"27965_CR9","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.31.1800461","volume":"24","author":"A Mira-Iglesias","year":"2019","unstructured":"Mira-Iglesias, A. et al. Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017\/18 influenza season. Euro Surveill. 24(31), 1800461 (2019).","journal-title":"Euro Surveill."},{"issue":"39","key":"27965_CR10","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.39.1800092","volume":"23","author":"RG Pebody","year":"2018","unstructured":"Pebody, R. G. et al. Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010\/11 to 2016\/17. Euro Surveill. 23(39), 1800092 (2018).","journal-title":"Euro Surveill."},{"issue":"2","key":"27965_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/21645515.2017.1373227","volume":"14","author":"A Cruz-Valdez","year":"2018","unstructured":"Cruz-Valdez, A. et al. MF59-adjuvanted influenza vaccine (FLUAD(R)) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone(R)): A randomized, multicenter, Phase III pediatric trial in Mexico. Hum. Vaccines Immunother. 14(2), 386\u2013395 (2018).","journal-title":"Hum. Vaccines Immunother."},{"issue":"11","key":"27965_CR12","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.vaccine.2019.01.052","volume":"37","author":"P Haber","year":"2019","unstructured":"Haber, P. et al. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018. Vaccine 37(11), 1516\u20131520 (2019).","journal-title":"Vaccine"},{"issue":"45","key":"27965_CR13","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1016\/j.vaccine.2009.02.004","volume":"27","author":"T Vesikari","year":"2009","unstructured":"Vesikari, T. et al. MF59-adjuvanted influenza vaccine (FLUAD) in children: Safety and immunogenicity following a second year seasonal vaccination. Vaccine 27(45), 6291\u20136295 (2009).","journal-title":"Vaccine"},{"issue":"6","key":"27965_CR14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., Arunachalam, P. S. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20(6), 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"27965_CR15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4), 492\u2013503 (2010).","journal-title":"Immunity"},{"issue":"3","key":"27965_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00492-17","volume":"8","author":"KA Gregg","year":"2017","unstructured":"Gregg, K. A. et al. Rationally designed TLR4 ligands for vaccine adjuvant discovery. MBio 8(3), e00492-17 (2017).","journal-title":"MBio"},{"issue":"28","key":"27965_CR17","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1016\/j.vaccine.2018.05.101","volume":"36","author":"KA Gregg","year":"2018","unstructured":"Gregg, K. A. et al. A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model. Vaccine 36(28), 4023\u20134031 (2018).","journal-title":"Vaccine"},{"issue":"36","key":"27965_CR18","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1016\/j.vaccine.2021.06.085","volume":"39","author":"RE Haupt","year":"2021","unstructured":"Haupt, R. E. et al. Novel TLR4 adjuvant elicits protection against homologous and heterologous influenza A infection. Vaccine 39(36), 5205\u20135213 (2021).","journal-title":"Vaccine"},{"issue":"1","key":"27965_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.chom.2018.06.016","volume":"24","author":"L Coughlan","year":"2018","unstructured":"Coughlan, L. & Palese, P. Overcoming barriers in the path to a universal influenza virus vaccine. Cell Host Microbe 24(1), 18\u201324 (2018).","journal-title":"Cell Host Microbe"},{"issue":"4","key":"27965_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.immuni.2017.09.007","volume":"47","author":"CI Paules","year":"2017","unstructured":"Paules, C. I. et al. The pathway to a universal influenza vaccine. Immunity 47(4), 599\u2013603 (2017).","journal-title":"Immunity"},{"issue":"5","key":"27965_CR21","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.ymthe.2022.01.011","volume":"30","author":"CM Bliss","year":"2022","unstructured":"Bliss, C. M. et al. A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. Mol. Ther. 30(5), 2024\u20132047 (2022).","journal-title":"Mol. Ther."},{"issue":"3","key":"27965_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003207","volume":"9","author":"BJ Laidlaw","year":"2013","unstructured":"Laidlaw, B. J. et al. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog. 9(3), e1003207 (2013).","journal-title":"PLoS Pathog."},{"issue":"6254","key":"27965_CR23","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1126\/science.aac7263","volume":"349","author":"A Impagliazzo","year":"2015","unstructured":"Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349(6254), 1301\u20131306 (2015).","journal-title":"Science"},{"issue":"1","key":"27965_CR24","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41467-017-00928-3","volume":"8","author":"W He","year":"2017","unstructured":"He, W. et al. Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. Nat. Commun. 8(1), 846 (2017).","journal-title":"Nat. Commun."},{"issue":"8","key":"27965_CR25","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.vaccine.2005.08.105","volume":"24","author":"K Goodwin","year":"2006","unstructured":"Goodwin, K., Viboud, C. & Simonsen, L. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine 24(8), 1159\u20131169 (2006).","journal-title":"Vaccine"},{"issue":"2","key":"27965_CR26","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","volume":"126","author":"DJ DiLillo","year":"2016","unstructured":"DiLillo, D. J. et al. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Investig. 126(2), 605\u2013610 (2016).","journal-title":"J. Clin. Investig."},{"issue":"2","key":"27965_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm.3443","volume":"20","author":"DJ DiLillo","year":"2014","unstructured":"DiLillo, D. J. et al. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 20(2), 143\u2013151 (2014).","journal-title":"Nat. Med."},{"issue":"4","key":"27965_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005578","volume":"12","author":"GS Tan","year":"2016","unstructured":"Tan, G. S. et al. Broadly-reactive neutralizing and non-neutralizing antibodies directed against the H7 influenza virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathog. 12(4), e1005578 (2016).","journal-title":"PLoS Pathog."},{"issue":"2","key":"27965_CR29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1128\/JVI.02275-15","volume":"90","author":"TJ Wohlbold","year":"2016","unstructured":"Wohlbold, T. J. et al. Hemagglutinin stalk- and neuraminidase-specific monoclonal antibodies protect against lethal H10N8 influenza virus infection in mice. J. Virol. 90(2), 851\u2013861 (2016).","journal-title":"J. Virol."},{"issue":"1","key":"27965_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1073\/pnas.1715471115","volume":"115","author":"DD Raymond","year":"2018","unstructured":"Raymond, D. D. et al. Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. Proc. Natl. Acad. Sci. U.S.A. 115(1), 168\u2013173 (2018).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"27965_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-042617-053214","volume":"37","author":"D Masopust","year":"2019","unstructured":"Masopust, D. & Soerens, A. G. Tissue-resident T cells and other resident leukocytes. Annu. Rev. Immunol. 37, 521\u2013546 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"27965_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.559382","volume":"11","author":"B Kingstad-Bakke","year":"2020","unstructured":"Kingstad-Bakke, B. et al. Polymeric pathogen-like particles-based combination adjuvants elicit potent mucosal T cell immunity to influenza A virus. Front. Immunol. 11, 559382 (2020).","journal-title":"Front. Immunol."},{"key":"27965_CR33","volume":"81","author":"I Margine","year":"2013","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. 81, e51112 (2013).","journal-title":"J. Vis. Exp."},{"issue":"8","key":"27965_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043603","volume":"7","author":"F Krammer","year":"2012","unstructured":"Krammer, F. et al. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS\u00a0One 7(8), e43603 (2012).","journal-title":"PLoS\u00a0One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27965-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T06:21:25Z","timestamp":1673590885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27965-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["27965"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-27965-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2079146\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-2079146\/v2","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"10 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccines which list FK as inventor. In addition, FK is currently consulting for Pfizer, Third Rock Ventures and Avimex. MF received royalties\/licenses from Aikido Pharma for antiviral drug patent licensing, consulting fees from Aikido Pharma, Observatory Group, for consulting for COVID-19, and participation on Scientific Advisory Board for Aikido Pharma, outside the submitted work. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"715"}}